Inhalable Biologics Global Market Report 2025

The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.9 billion in 2029 at a compound annual growth rate (CAGR) of 16%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.

The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.

Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.

In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma’s expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.

Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‑La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market research report is one of a series of new reports that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.